Fusion Antibodies, a specialised Contract Research Organisation (CRO) operating in the field of monoclonal antibody engineering and production, has provided an update on trading for the year ending 31 March 2019. Despite the H219 sales recovery and a building order book, several orders are expected to be closed post year end. As a result, FY19 revenues - of at least £2.1m - fall well below our expectations.
25 Feb 2019
Momentum building in H2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Momentum building in H2
Fusion Antibodies Plc (FAB:LON) | 3.8 0 (-1.3%) | Mkt Cap: 3.58m
- Published:
25 Feb 2019 -
Author:
Emma Ulker -
Pages:
3
Fusion Antibodies, a specialised Contract Research Organisation (CRO) operating in the field of monoclonal antibody engineering and production, has provided an update on trading for the year ending 31 March 2019. Despite the H219 sales recovery and a building order book, several orders are expected to be closed post year end. As a result, FY19 revenues - of at least £2.1m - fall well below our expectations.